DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTDevelopment and Manufacturing Services Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of July 17, 2013 (the “Effective Date”) by and between RHYTHM METABOLIC, INC., a Delaware corporation with offices at 855 Boylston Street, 11th Floor, Boston, MA 02116, USA (“Rhythm”) and PEPTISYNTHA Inc., a US company incorporated under the laws of the state of Delaware with its registered office at 3333 Richmond Avenue, Houston Texas 77098, USA (“Manufacturer”).
LICENSE AGREEMENT BETWEEN IPSEN PHARMA SAS AND RHYTHM METABOLIC, INC.License Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into on March 21, 2013 by and between, on the one hand, IPSEN PHARMA S.A.S., a French corporation, with its principal office at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France, on behalf of itself and its Affiliates (collectively, “Ipsen”), and, on the other hand, RHYTHM METABOLIC, INC., a corporation organized under the laws of the State of Delaware, U.S.A., with its principal office at 855 Boylston Street, 11th Floor, Boston MA 02116, on behalf of itself and its Affiliates (collectively, “Licensee”), and is effective as of the Effective Date (as defined below).
LICENSE AGREEMENT BY AND BETWEEN CAMURUS AB AND RHYTHM PHARMACEUTICALS, INC.License Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • England
This License Agreement is made as off the Effective Date (hereinafter defined) between Camurus AB, a limited liability company organized and existing under the laws of Sweden and having its principal place of business at Ideon Science Park, Sölvegatan 41, SE-223 70 Lund, Sweden (“Camurus”) and Rhythm Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having its principal place of business at 855 Boylston Street, 11th Floor, Boston, MA 02116 USA (“Rhythm”) (each a “Party” and collectively, the “Parties”)
RHYTHM PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTAdoption Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 21st day of August, 2017, by and among (i) Rhythm Pharmaceuticals, Inc. (formerly known as Rhythm Metabolic, Inc.), a Delaware corporation (the “Company”), (ii) each of the persons listed on Schedule A hereto (the “Initial Investors”), and (iii) each person who hereafter becomes a party to this Agreement in accordance with Subsection 6.1 or Subsection 6.9 hereof.
DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTDevelopment and Manufacturing Services Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • England
THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of December 21, 2016 (the “Effective Date”) by and between RHYTHM PHARMACEUTICALS, INC., a Delaware corporation with offices at 500 Boylston Street, 11th Floor, Boston, MA 02116, USA (“Rhythm”) and RECIPHARM MONTS SAS, a French corporation with an office at 18 route de Montbazon, 37 260 Monts, France (“Manufacturer”).
AMENDED AND RESTATED PAYROLL SERVICES AGREEMENTPayroll Services Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This AMENDED AND RESTATED PAYROLL SERVICES AGREEMENT, dated as of March 21, 2013 (the “Agreement”), by and between RHYTHM METABOLIC, INC., a Delaware corporation (“Metabolic”) and RHYTHM PHARMACEUTICALS, INC., a Delaware corporation (“Pharmaceuticals”).
LEASE between 500 BOYLSTON & 222 BERKELEY OWNER (DE) LLC, as LANDLORD and RHYTHM PHARMACEUTICALS, INC., as TENANT Dated as of November 25, 2015Lease • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This “Basic Lease Information Sheet” is made a part of, and incorporated in, that certain leas dated by and between 500 Boylston & 222 Berkeley Owner (DE) LLC (as “Landlord”) and Rhythm Pharmaceuticals, Inc. (as “Tenant”).
RHYTHM PHARMACEUTICALS, INC. CONSULTING AGREEMENTConsulting Agreement • September 5th, 2017 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This CONSULTING AGREEMENT (this “Agreement”) is entered into as of June 12, 2017 (“Effective Date”), by and between Rhythm Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Bart Henderson (the “Consultant”).
